Macular Edema
Conditions
Keywords
macular edema secondary to retinal benous occlusion
Brief summary
Although it is important in the clinical management to classify BRVO into subtypes based on the location of the occlusion (major or macular), few studies have provided such information\[8,9\]. The aim of this study was to evaluate the outcome of patients with macular edema due to Branch retinal vein occlusion who were treated with intravitreal bevacizumab injection and to determine the concentrations of cytokines in the aqueous humor according to the site of the occlusion.
Detailed description
Branch retinal vein occlusion is the second most frequent major retinal vascular disease after diabetic retinopathy. One of the main reasons for visual loss in BRVO is the development of macular edema. Treatment options for BRVO include grid laser treatment, intravitreal injection of steroids, surgical procedures, and off-label treatment with intravitreal anti-vascular endothelial growth factor (VEGF) agents. During recent years, intravitreal anti-VEGF treatment with bevacizumab has been shown to efficiently reduce macular edema and improve visual acuity in numerous case series and prospective or retrospective studies.
Interventions
PROCEDUREintravitreal bevacizumab
Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
Sponsors
Hallym University Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* macular edema involving the center of the fovea with a minimum central macular thickness at baseline of ≥250 μm
Exclusion criteria
* previous vitreoretinal surgery, intravitreal injections or laser treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| efficacy of intravitreal bevacizumab | baseline and 12 months after initial injection | the number on intravitreal bevacizumab during follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cytokine levels in aqueous humor | before intravitreal injection | cytokine levels in aqueous humor before bevacizumab injection |
Countries
South Korea
Outcome results
None listed